Systemic AL (λ) Amyloidosis Discovered After Neoadjuvant Pembrolizumab‐Based Chemoimmunotherapy for Resectable NSCLC: Case Report

ABSTRACT Systemic AL amyloidosis is rarely reported in temporal association with immune checkpoint inhibitor use. We report a 69‐year‐old man with resectable stage IIB right upper lobe lung adenocarcinoma who received neoadjuvant pembrolizumab, carboplatin, and pemetrexed followed by robotic‐assiste...

Cijeli opis

Bibliografski detalji

Glavni autori:	Weijie Ma, Dana M. Ferrari‐Light, Liang Lu
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2026-04-01
Serija:	Respirology Case Reports
Teme:	AL amyloidosis immune checkpoint inhibitor lung adenocarcinoma neoadjuvant immunotherapy
Online pristup:	https://doi.org/10.1002/rcr2.70586
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!